1. Market Research
  2. > Pharmaceutical Market Trends
What do Patients want from Pharma? The Real Patient-Centric Perspective

What do Patients want from Pharma? The Real Patient-Centric Perspective

  • July 2017
  • ID: 5175262
  • Format: PDF
  • By Firstword Pharma

Summary

Table of Contents

What do Patients want from Pharma?

How can pharma leverage patient insights to deliver the support they want?

Is patient centricity coming of age? The patient voice is becoming increasingly influential and patient groups are looking to pharma for practical and sustained support. But what services do patients want, how do they want them delivered, how do they see their role and what are the commercial and research benefits for industry? As healthcare systems migrate to a pay-for-performance model, the patient/pharma relationship can be a win-win, but only if companies learn from patients and embed a patient centric approach across their organisation.

For a real patient-centric perspective turn to What do Patients want from Pharma 2017? In this revealing report, 12 US and EU patient experts representing a wide-range of patient views identify the critical support services that would really drive better clinical trial recruitment/design, promote the development of more effective medicines, and improve patient adherence and outcomes.

Report Features

Unique and candid insights from US and EU patient advocacy experts
Key actionable insights for how pharma can listen to and learn from patients to deliver more effective clinical research, better products, and improve patient engagement, adherence and outcomes
Figure: Ten principles of patient centricity: Astra Zeneca’s view
Figure: The challenges and benefits of adopting a patient centric model
Figure: Patient tools and services provided by pharma
Figure: Top 10 patient services driving above average business impact
Figure: Recent innovative patient initiatives and services from companies such as Roche, UCB. AbbVie, Novartis and Takeda
Figure: Key stages in a patient support framework
Figure: Framework for patient and family engagement in health
Figure: The US HIPPA Act
Figure: The percentage of companies investing/expected to invest in patient services -- 2016 versus 2018
Figure: Opportunities for patient involvement in drug R&D
Insight: Key tips on clinical trial recruitment and retention – a patient advocate’s view
Insight: Key tips on developing patient centric materials – a patient advocate’s view
Case Study: The EUPATI project
Case Study: Acromegaly: The role of the patient advocate
Case Study: Online clinical trial guide from Eli Lilly
Case Study: The EU Patients’ and Consumers Working Party
Case Study: The Patient-Centred Outcomes Research Project
SWOT analysis of the patient/pharma relationship and its future

Key Benefits:

Understand how patient groups see their role developing across pharma’s business interests
Identify the critical services and support that patients want from pharma
Appreciate the challenges of distributing health education to all patients and propose solutions
Benefit from the early patient involvment in the drug development process.
Know which digital technologies and services are revolutionising pharma/patient communications
Plan organisational changes to ensure the whole company is working to a patient centric agenda
Understand the US and EU regulatory frameworks that govern – and sometimes impede – pharma’s patient communications

Key Questions Answered by This Report:

Expanding role: In what areas is patient input now essential and what are the benefits of getting this engagement right?
Getting the message out: Research indicates that only 1 in 5 patients are aware of available support services – what can you do to address this deficit?
Point of Contact: Why is having a single liaison point in pharma important to patients and what are the operational implications for companies?
Early Clinical Engagement: What are the benefits to pharma of engaging with patients early in the drug development process?
Digital future: Digital technology is driving patient support services – but what technologies and techniques are delivering real benefits?
Country variables: National health service provision along with social and cultural attitudes affect patient needs and responses – how can pharm meet these diverse challenges?
Regulatory burden: What are the current regulations governing pharma/patient communications and is it time for a fundamental rethink?

Expert Views

Each patient advocacy expert has been carefully selected for their practical experience and detailed current knowledge of the pressures and opportunities in the patient/pharm relationship. They represent a wide-range of disease specific and pan-regional views across Europe and the US.

Carmen Gonzalez: Government Affairs y Patient Advocacy, Relaciones con Pacientes Corporate Affairs, Spain
Denis Hogan: Executive Director, European Alliance for Personalised Medicine, UK
Dr Antonio Ciaglia: Policy Manager, International Alliance of Patients’ Organizations, UK
Gary Petersen: Patient Advocate and Founder, Myeloma Survival, USA
Ines Alves: Patient Advocate and Founding Board Member EUPATI, Portugal and European Reference Networks - Patient representative in the Rare Bone Diseases Group
Jenny Sharpe: Patient and advocate, Muscular Dystrophy UK, UK
Jenny Ahlstrom: President, Founder, Multiple Myeloma Patient and Board Member, USA
Jess Bateman: Patient and Research Advocacy at American Urological Association, USA
Jill Sisco: Patient Advocate, President of the Acromegaly Community, USA
Peggy Gibson Carroll: Managing Partner, Patient Alliances, USA
Tamás Bereczky: Patient Advocate, EUPATI, Germany Communications Advisor of the European AIDS Treatment Group
Wendy Booker: Patient Advocacy Consultant, Keynote and Motivational Speaker, USA

4 Key Quotes

“There are many restrictions between pharmaceutical companies and patients and we need to work together to change the rules. We need to break some intricate old boundaries to improve communication.”Ines Alves Patient Advocate and Founding Board Member EUPATI, Portugal

“Pharma have created a lot of programmes, but patients aren’t aware of them. Pharma need to figure out the best channel to ensure that patients are aware of all the resources that are available, whether that is through the advocacy channel, websites, or physicians and nurses, to get these resources into the patients’ hands. Everyone could benefit from programmes that are more visible through the nurse, physician or the advocacy groups to connect with patients and caregivers.” Peggy Gibson Carroll Managing Partner, Patient Alliances

“Patient advocates can help pharma guide companies and clinical research organisations to the right patient populations and we can relay the unmet needs to pharma and translate clinical information into lay people’s language. This benefits both parties; it saves lives as patients get access to essential medicines and patient groups grow as they get better at their jobs. Patient groups can also act as mediators between companies and regulators or vice versa.”Tamás Bereczky, EUPATI, Germany Communications Advisor of the European AIDS Treatment Group

“It is important that we integrate the patient perspective at the earliest stage when treatments are being developed at a research level, as well as the clinical trial stages. When a clinical trial finishes and if the treatment has a beneficial effect on certain patients, then these patients should get access to the same type of treatment. The whole ethical issue surrounding placebos needs to be looked at; there must be a better way to do trials in a more patient-centric manner.”Denis Hogan,Executive Director, European Alliance for Personalised Medicine

Content Highlights

Executive summary
Research objectives and methodology
Patient centricity
Key insights
What is patient centricity? 
What are the perceived benefits of adopting a patient centric model? 
Where are we regarding the adoption of patient centric business models? 
What are the main barriers of adopting a patient centric model? 
How patients currently interact with pharma
Key insights
What do patient-centric services entail? 
What modalities are popular? 
Recent innovative patient services/initiatives
How do companies promote these programmes? 
How do companies implement these programmes? 
Patient Support Frameworks
Patient Engagement
Engagement with PAOs
Financial influence on PAOs
Patient partnerships
Patient led educational meetings
Problems and potential solutions in designing and implementing patient centric services
Key insights: 
A multichannel approach is required
Communicating with online communities
Pharma need to increase the visibility of services
Health literary and disease awareness needs to be improved
Patient services vary by country and disease area
What are the barriers to greater engagement? 
Key Insights
Regulatory and legislative hurdles
The HIPAA Act
Pharma Codes of Conduct
Trust and transparency between patients and pharma
The quality of information and language differences
What will it look like in the future? 
Key insights
New services will be driven by patient outcomes
Patient partnerships will play a central role
Technology driven offerings will increase level of engagement and patient support
What pharma needs from patients
Key insights
Greater regulatory support for patient participation
Greater patient involvement during the R&D process
Increased patient involvement in clinical trial design and endpoints
Patients can assist with identification and recruitment
Patients can help pharma better understand their preferences relevant content
Patients can assist in the development of marketing materials and product packaging
What patients need from pharma
Key insights
Patients need tangible information about clinical trial enrolment
Pharma need to improve communication to patients during trials
Pharma needs to disseminate fair, trustworthy information
Pharma needs patients to be active participants to drive actionable outcomes
Patient wish list for pharma
SWOT Analysis


Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2020

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H1 2020, provides ...

Rocklatan (netarsudil and latanoprost ophthalmic solution) - Drug Insight and Market Forecast - 2030

Rocklatan (netarsudil and latanoprost ophthalmic solution) - Drug Insight and Market Forecast - 2030

  • $ 2750
  • February 2020

Overview“Rocklatan (netarsudil and latanoprost ophthalmic solution) - Drug Insight and Market Forecast – 2030” report outlays comprehensive insights of the product indicated for the treatment of ...

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2020

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2020

  • $ 2000
  • January 2020

Venous Leg Ulcers (Crural ulcer) - Pipeline Review, H1 2020SummaryThe latest Pharmaceutical and Healthcare disease pipeline guide Venous Leg Ulcers (Crural Ulcer) - Pipeline Review, H1 2020, provides an ...


ref:plp2017

Reportlinker.com © Copyright 2020. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on